Many patients with congestive heart failure remain symptomatic and functionally limited, despite optimal conventional therapy with diuretics, digitalis, and vasodilators/converting enzyme inhibitors. It has seemed reasonable that new, non-digitalis-like positive inotropic agents would be useful adjunctive therapy in such patients. Despite a major effort over the last decade, none of the new positive inotropic agents has yet been shown to be both efficacious and safe for long-term oral administration to patients with heart failure. Nevertheless, substantial progress has been made in this area with the development of several new agents acting by novel mechanisms, including cardioselective phosphodiesterase inhibition (eg, milrinone), calcium sensitization (eg, pimobendan), and ion channel modulation (eg, OPC-8212). At least three of the new positive inotropic agents, milrinone, pimobendan, and OPC-8212, have now been shown to improve exercise capacity and clinical status in appropriate clinical trials. The recent finding that milrinone may increase mortality in patients with severe NYHA class IV congestive heart failure has had a sobering effect but does not exclude the possibility that this agent, or another phosphodiesterase inhibitor, might be used safely in lower doses and does not speak to the safety of newer agents that act, at least in part, by mechanisms other than phosphodiesterase inhibition. Much more work will be needed to understand if the existing, or as yet to be developed, positive inotropic agents can be involved in the long-term management of patients with congestive heart failure. (Cardiol Rev 1993;1:42-49)